A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Celltrion Healthcare logo

Celltrion Healthcare




Essential Hypertension


Drug: Azilsartan Medoxomil

Study type


Funder types



U1111-1252-3589 (Registry Identifier)

Details and patient eligibility


The purpose of this study is to evaluate the safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on the precaution in the use, ADRs already known, non-serious ADRs and other safety related information (laboratory values changes, etc).

Full description

This is a long-term prospective, observational post-marketing surveillance study of azilsartan medoxomil in participants with essential hypertension. This study will assess the safety and effectiveness of azilsartan medoxomil prescribed as a monotherapy or taken concomitantly with other anti-hypertension therapies in real-world clinical practice settings. The study will enroll approximately 3000 participants. The data will be prospectively collected, at the centers from medical files and recorded into electronic case report forms (e-CRFs). All the participants will be assigned to a single observational cohort: Participants With Essential Hypertension The multi-center study will be conducted in South Korea. Data collection will be based on routinely scheduled and emergency visits over the surveillance period, scheduled at Visit 1 (Baseline), Visit 2 (6 Weeks), Visit 3 (3 Months or more less than 6 Months) and Visit 4 (6 Months or more [Month 9]). The overall duration of the study will be approximately 6 years. All participants will be followed up for 9 months after drug administration.


3,438 patients




18+ years old


No Healthy Volunteers

Inclusion criteria

With Essential Hypertension.

  • Newly diagnosed with essential hypertension or who have no long-term history of hypertension medication after diagnosis (The participant has a SBP or DBP >=140 or 90 mmHG, respectively).
  • Receiving treatment with other hypertension medications.
  • Newly prescribed and initiates azilsartan medoxomil for the treatment of hypertension, as a monotherapy or taken concomitantly with other anti-hypertension therapies.

Exclusion criteria

  • Treated with azilsartan medoxomil outside of the locally approved label in South Korea.
  • With known hypersensitivity or presence of any contraindication to azilsartan medoxomil.
  • Use of aliskiren in combination with azilsartan medoxomil in participants with diabetes or with moderate to severe renal impairment (glomerular filtration rate [GFR ] < 60 milliliter per minute [mL/min]/1.73 m^2).

Trial design

3,438 participants in 1 patient group

Participants With Essential Hypertension
Participants diagnosed with essential hypertension and whom have been prescribed azilsartan medoxomil as a monotherapy or taken concomitantly with other anti-hypertension therapies in a routine clinical practical setting, will be observed prospectively over a period of 6 years.
Drug: Azilsartan Medoxomil

Trial contacts and locations



Central trial contact

Takeda Study Registration Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems